Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Duloxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 13/20 | 0.98 |
| ▸ | SLC6A4 known ✓ | P31645 | 13/20 | 0.98 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.98 |
| ▸ | MLNR | O43193 | 1/20 | 0.98 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.98 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.98 |
| ▸ | HTR1A | P08908 | 1/20 | 0.98 |
| ▸ | GAA | P10253 | 1/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.98 |
| ▸ | DRD2 | P14416 | 1/20 | 0.98 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.98 |
| ▸ | HTR2A | P28223 | 1/20 | 0.98 |
| ▸ | HTR2C | P28335 | 1/20 | 0.98 |
| ▸ | MC4R | P32245 | 1/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Duloxetine SCHEMBL120750 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL119403 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL29389952 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| (R)-Duloxetine SCHEMBL3901869 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| (R)-Duloxetine SCHEMBL30523711 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL647773 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL28196267 | 0.99 | SLC6A2 (0.95) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL3803 | 0.99 | SLC6A4 (1.00) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL10036575 | 0.99 | SLC6A4 (1.00) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL8291 | 0.99 | SLC6A4 (1.00) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2544667-B1 | ALCOHOL RESISTANT ENTERIC PHARMACEUTICAL COMPOSITIONS | ALKERMES PHARMA IRELAND LTD (IE) | 2018-11-14 | — | — | EP | disclosed |
| US-20180085315-A1 | ALCOHOL RESISTANT ENTERIC PHARMACEUTICAL COMPOSITIONS | ALKERMES PHARMA IRELAND LTD (IE) | 2018-03-29 | — | — | US | disclosed |
| US-20140248341-A1 | ALCOHOL RESISTANT ENTERIC PHARMACEUTICAL COMPOSITIONS | ALKERMES PHARMA IRELAND LIMITED (IE) | 2014-09-04 | — | — | US | disclosed |
| US-20110223244-A1 | ALCOHOL RESISTANT ENTERIC PHARMACEUTICAL COMPOSITIONS | ELAN PHARMA INTERNATIONAL LIMITED (IE) | 2011-09-15 | — | — | US | disclosed |
| WO-2009087657-A2 | STABLE PHARMACEUTICAL COMPOSITION OF DULOXETINE AND PROCESS FOR ITS PREPARATION | ALKEM LABORATORIES LTD. (IN) | 2009-07-16 | — | — | WO | disclosed |
| EP-1976845-A2 | A PROCESS FOR THE PREPARATION OF (S)-(+)-N,N-DIMETHYL-3-(1-NAPHTHALENYLOXY)-3-(2-THIENYL)PROPANAMINE, A DULOXETINE INTERMEDIATE | Teva Pharmaceutical Industries Ltd (IL) | 2008-10-08 | — | — | EP | disclosed |
| US-20070292511-A1 | Duloxetine hydrochloride delayed release formulations | TEVA PHARMACEUTICALS USA, INC. | 2007-12-20 | — | — | US | disclosed |
| WO-2007095200-A2 | A PROCESS FOR THE PREPARATION OF (S)-(+)-N,N-DIMETHYL-3-(1-NAPHTHALENYLOXY)-3-(2-THIENYL)PROPANAMINE, A DULOXETINE INTERMEDIATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070292511-A1 | Duloxetine hydrochloride delayed release formulations | SI, SLC6A4, HTR5A | SLC6A2 4/4885SLC6A4 2/4885SLC6A3 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.